SEC Comment Letter 0000000000-23-005238 to ETHEMA HEALTH Corp (GRST) (CIK 0000792935) (GRST)

ETHEMA HEALTH Corp (GRST) (CIK 0000792935)
Date: May 16, 2023 · CIK: 0000792935 · Accession: 0000000000-23-005238

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-12027

Date

May 16, 2023

Author

Services

Form

UPLOAD

Company

ETHEMA HEALTH Corp (GRST) (CIK 0000792935)

Letter

United States securities and exchange commission logo May 16, 2023 Shawn Leon Chief Executive Officer ETHEMA HEALTH Corp 950 Evernia Street West Palm Beach, Florida 33401 Re:ETHEMA HEALTH Corp Offering Statement on Form 1-A Post Qualification Amendment No. 1 Filed May 4, 2023 File No. 024-12027 Dear Shawn Leon: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at 202-551-4511 with any questions.

Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services

Show Raw Text

United States securities and exchange commission logo
May 16, 2023
Shawn Leon
Chief Executive Officer
ETHEMA HEALTH Corp
950 Evernia Street
West Palm Beach, Florida 33401
Re:ETHEMA HEALTH Corp
Offering Statement on Form 1-A
Post Qualification Amendment No. 1
Filed May 4, 2023
File No. 024-12027
Dear Shawn Leon:
            This is to advise you that we do not intend to review your amendment.
            We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Jessica Ansart at 202-551-4511 with any questions.

Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services

SecProbe.io